LAMINITIS
DRUG TREATMENT SAVING HORSE'S LIVES
Private Placement Offering Event Set for June 27th at Lone
Star Park
DENVER, Colorado -- June 13, 2014 - Willowcroft
Pharm, Inc., developer of the successful laminitis drug treatment, Laminil,
announced today that it is offering up to 60,000,000 shares of preferred stock at a
price of $0.08333 ...